The efficacy and safety of multilamellar vesicle containing retinaldehyde: A double-blinded, randomized, split-face controlled study

J Cosmet Dermatol. 2021 Sep;20(9):2874-2879. doi: 10.1111/jocd.13993. Epub 2021 Feb 18.


Background: Retinaldehyde is one of the major members of the retinoid family, which has potential skin rejuvenating effects on photoaged skin and has a good safety profile.

Aims: The study aimed to evaluate the efficacy and safety of multilamellar vesicle containing retinaldehyde (MLV-RAL) 0.05% and 0.1% used to treat photoaged skin.

Patients and methods: A randomized, prospective, investigator-blinded, split-face comparison study was conducted. We enrolled 23 Korean volunteers who applied MLV-RAL 0.05%/0.1% cream on one randomized side of their face and retinol 0.05%/0.1% cream on the opposite side. Wrinkle depth on both crow's feet was assessed by the Antera 3D system. Skin hydration, elasticity, facial curved length, and dermal density were also evaluated.

Results: After an 8-week application, all objective parameters, including wrinkle depth, were significantly improved in both MLV-RAL 0.05%/0.1% and retinol 0.05%/0.1% treated sides. Compared with the retinol-treated side, MLV-RAL-treated side showed a significant improvement of objective assessments except for dermal density. Additionally, there was no adverse event associated with the use of either MLV-RAL 0.05%/0.1% or retinol 0.05%/0.1% cream.

Conclusion: The application of MLV-RAL 0.05%/0.1% cream improved wrinkle, facial contour, and biophysical parameters associated with skin aging.

Keywords: cosmeceuticals; photoaged skin; retinaldehyde; retinoic acid.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Humans
  • Prospective Studies
  • Retinaldehyde*
  • Skin Aging*
  • Skin Cream
  • Treatment Outcome


  • Retinaldehyde